One of the most interesting stories on the OTC over the past few months is surely Generex Biotechnology Corporation (OTCMKTS:GNBT). Not only has this small-float stock been red-hot, but it is a rare example of a large-dividend paying play trading over the counter — the ex-dividend date at the end of November is why charts on some interfaces seemingly show a big drop (it isn’t a drop). To further flesh out the story, the company just announced that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted European Patent No. 2983616 entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.”
According to the release, “The Company’s patent secures market exclusivity for its key product. Regentys ECMH is a novel application of extracellular matrix technology using a hydrogel bio-scaffold to enable the body to protect damaged tissue as it undertakes its natural healing process. Regentys ECMH is a first-in-class therapy for patients suffering from Ulcerative Colitis (UC), an inflammatory bowel disease that affects an estimated 2 million people in Europe and 1 million in the United States. This specific patent provides exclusive market protection in the European Union for the company’s ECMH technology that is being developed for global markets; patents are pending in the United States and China. In addition to the UC treatment indication, Regentys is developing ECMH to treat other inflammatory bowel diseases, including Crohn’s Disease, which affects an additional 2 million people in the EU and U.S.”
Generex Biotechnology Corporation (OTCMKTS:GNBT) bills itself as a company that, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States.
It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices.
The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.
According to company materials, “Generex Biotechnology Corp. (GNBT) is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our company creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. The company goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.”
Find out when $GNBT reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, GNBT just announced that Regentys Corporation (formerly Asana Medical, Inc.), a clinical stage regenerative medicine company contracted to become a subsidiary of Generex, was granted European Patent No. 2983616 entitled “Method And Composition For Treating Inflammatory Bowel Disease Without Colectomy.”
In all, recent action has seen 42% during the past month in terms of shareholder gains in the listing. Moreover, the stock has benefitted from a jump in recent trading volume to the tune of just under 220% beyond its prior sustained average level.
This is particularly important with a float in play that’s tight — of 19M shares.
“As we advance our platform approach for the treatment of ulcerative colitis, and other inflammatory bowel diseases (`IBD’), we are mindful of the value of building an intellectual property portfolio that supports our proprietary formulations, applications and therapies,” said Rick Bulman, Chief Executive Officer of Regentys Corporation. “We are pleased to have been granted the ‘616 patent as a recognition of our efforts. UC really impacts the quality of life of patients and we look forward to advancing our translational research program into the clinic, where we expect to initiate first-in-human studies of Regentys ECMH™ in Q3 2019.”
Now commanding a market cap of $40.69M, GNBT has a reserve ($1M) of cash on the books, which stands against about $25.2M in total current liabilities. GNBT is pulling in trailing 12-month revenues of $703K. However, the company is seeing recent declines on the top-line on a sequential quarterly basis, with revenues falling at 0% as of its latest reporting period. This is an exciting story, and we look forward to a follow-up chapter as events transpire. Sign-up for continuing coverage on shares of $GNBT stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $GNBT, either long or short, and we have not been compensated for this article.